Editorial: Hyperhemolysis syndrome in sickle cell disease

Expert Review of Hematology

Volumn 2, Issue 2, 2009, Pages 111-115

  Win, Nay ^a  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ERYTHROPOIETIN; HEMOGLOBIN A; HEMOGLOBIN S; HLA ANTIBODY; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; PREDNISOLONE; STEROID; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CHEST SYNDROME; ALLOIMMUNIZATION; ANEMIA; BLOOD TRANSFUSION REACTION; CELL ADHESION; CLINICAL FEATURE; COOMBS TEST; CYTOLYSIS; DRUG MECHANISM; DRUG POTENTIATION; EDITORIAL; ENDOTHELIUM CELL; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FATALITY; FEVER; HEMOGLOBINURIA; HEMOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERBILIRUBINEMIA; HYPERHEMOLYSIS SYNDROME; IMMUNOTHERAPY; INCIDENCE; LOW DRUG DOSE; MACROPHAGE ACTIVATION; MYELOFIBROSIS; NEOCYTOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; RETICULOCYTE COUNT; RETICULOCYTOSIS; SICKLE CELL ANEMIA; STEROID THERAPY; THALASSEMIA; BLOOD; BLOOD TRANSFUSION; REVIEW;

ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; HEMOLYSIS; HUMANS;

EID: 77953426119     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.2     Document Type: Editorial

References (31)

1. Friedman DF, Kim HC, Manno CS. Hyperhaemolysis associated with red cell transfusion in sickle cell disease. Transfusion 33(Suppl.), 148 (1993).
2. Petz LD, Calhoun L, Shulman I, Johnson C, Herron R. The sickle cell haemolytic transfusion reaction syndrome. Transfusion 37, 382-392 (1997).
3. Cullis JO, Win N, Dudley JM, Kaye T. Post transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction. Vox Sang. 4, 355-357 (1995).
4. Win N, Doughty H, Telfer P, Wild B, Pearson T. Hyperhaemolytic transfusion reaction in sickle cell disease. Transfusion 41, 323-328 (2001).
5. Win N, Tullie Y, Needs M, Chen PE, Okpala I. Use of intravenous immunoglobulin and intravenous methylprednisolone in hyperhaemolysis syndrome in sickle cell disease. Haematology 9, 433-436 (2004).
6. Win N, New H, Lee E, de la Fuente J. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion 48, 1231-1238 (2008).
7. Talano JM, Hillery CA, Gottschall JL, Baylerian DM, Scott JP. Delayed haemolytic transfusion reaction/ hyperhaemolysis syndrome in children with sickle cell disease. Pediatrics 111, 661-665 (2003).
8. King KE, Shirey RS, Lankjewicz MW, Young-Ramsaran J, Ness P. Delayed haemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells. Transfusion 37, 376-381 (1997).
9. Treleaven JG, Win N. Hyperhaemolysis syndrome in a patient with myelofibrosis. Haematology 9, 147-149 (2004).
10. Sirchia G, Moerelati F, Rebulla P. The sickle cell haemolytic transfusion reaction syndrome. Transfusion 37, 1098-1099 (1997).
11. Darabi K, Dzik S. Hyperhaemolysis syndrome in anaemia of chronic disease. Transfusion 45, 1930-1933 (2005).
12. Win N. Blood transfusion therapy for haemoglobulinopathies. In: Practical Management of Haemoglobinopathies. Okpala I (Ed.). Blackwell Publishing, Oxford, UK 99-106 (2004).
13. Petz LD, Garratty G. Bystander Immune Haemolysis Immune Haemolytic Anaemias (2nd Edition). Churchill Livingstone, PA, USA 358-364 (2004).
14. Garratty G. Severe reactions associated with transfusion of patients with sickle cell disease. Transfusion 37, 357-361 (1997).
15. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease potential role in the activation of vascular endothelium and vasoocclusion. Blood 96, 2451-2459 (2000).
16. Schwartz RS, Tanaka Y, Fidler IJ et al. Increased adherence of sickled and phosphatidylserine-enriched human erythrocytes to cultured human peripheral blood monocytes. J. Clin. Invest. 75, 1965-1972 (1985).
17. Gee BE, Platt OS. Sickle reticulocytes adhere to VCAM-1. Blood 85, 268-274 (1995).
18. Ihanus E, Uotila LM. Toivanen A, Varis M, Gahmberg CG. Red cell ICAM-4 is a ligand for the monocyte/machrophage integrin CD11c/CD18: characterization of the binding sites on ICAM-4. Blood 109, 802-810 (2007).
19. Takeuchi C, Ohto H, Miura S, Yasuda H, Ono S, Ogata T. Delayed and acute hemolytic transfusion reactions resulting from red cell antibodies and red cellreactive HLA antibodies. Transfusion 45, 1925-1929 (2005).
20. Muro M, Palacios S, Moya-Quiles R, Candela M, Alvarez-Lopez R. Acute haemolytic transfusion reactions secondary to human leukocyte antigen alloimmunization. Int. J. Lab. Hematol. 30(1), 84-86 (2008).
21. Anderson D, Ali K, Blanchette V et al. Guidelines on the use of intravenous immune globulin for haematologyic conditions. Transfusion Med. Rev. 21, S9-S56 (2007). (Pubitemid 46505088)
22. Provan D, Nokes TJC, Agrawal S, Winer J, Wood P. Clinical Guidelines for Immunoglobulin Use. Department of Health, London, UK (2008).
23. Packer JT, Greendyke RM, Swisher SN. The inhibition of erythrophagocytosis in vitro by corticosteroids. Trans. Assoc. Am. Phys. 73, 93-102 (1960).
24. Krause J, Wu R, Sherer Y, Patanick M, Peter JB, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations-a potential role for adjuvant intravenous immunoglobulin therapy in infectious disease. Transfusion Med. 12, 133-139 (2002).
25. Turhan A, Jenab P, Bruhns P, Ravetch JV, Coller BS, Frenette PS. Intravenous immune globulin prevents venula vaso-occlusion in sickle cell mice by inhibiting erythrocytes and adherent leuckocytes. Blood 15, 2397-2399 (2004).
26. Rhoades CJ, Williams MA, Kelsey SM, Newland AC. Monocyte-macrophage system as targets for immuno-modulation by intravenous immunoglobulin. Blood Rev. 14, 14-30 (2000).
27. Mota MA, Sakashita AM, Hamerschlak N, Kutner JM, Castilho LM. Post-transfusion hyperhaemolysis after haemolytic transfusion reaction in a patient with severe anaemia: case report. Vox Sang. 91(Suppl. 3), 125; (2006) (Abstract 233).
28. Sherwood JB, Goldwasser E, Chilcote R et al. Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood 67, 46-49 (1986).
29. Trial J, Rice L. Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial-macrophage interface. Curr. Pharmaceut. Design 10(2), 183-190 (2004).
30. Hebbel RP, Miller VB. Phagocytosis of sickle erythrocyte: immunological and oxidative determinants of haemolytic anemia. Blood 64, 733-741 (1984).
31. Mendoza E, Gutgsell N, Temple JD, Issitt P. Monocyte phagocyte activity in sickle cell disease. Acta Haematol. 85, 199-201 (1991).